Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02802345 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 274
- Enrollment target
NCT02802345 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 274 participants.
The verdict
NCT02802345, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 274 participants
- Enrollment target
Study Summary
To assess efficacy and safety of concomitant treatment with nintedanib and sildenafil in Idiopathic Pulmonary Fibrosis (IPF) patients with advanced lung function impairment.
Interventions
- DRUG Placebo
- DRUG Sildenafil
- DRUG Nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2016-06-30 |
| Est. Completion | 2018-04-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02802345
The ClinicalTrials.gov registry entry for NCT02802345 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02802345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02802345 about?
NCT02802345 is a clinical study titled "Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment". To assess efficacy and safety of concomitant treatment with nintedanib and sildenafil in Idiopathic Pulmonary Fibrosis (IPF) patients with advanced lung function impairment.
What is the current status of trial NCT02802345?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 274 participants. The study started on 2016-06-30. Estimated completion is 2018-04-13.
What interventions are being tested in trial NCT02802345?
The interventions under investigation include: Placebo (DRUG), Sildenafil (DRUG), Nintedanib (DRUG).
Who is sponsoring clinical trial NCT02802345?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.